Weight loss was dose-dependent, progressive from Week 1, and showed no plateau at 13 weeks suggesting longer treatment could produce substantially more weight loss
Khukhlina, .
Implications for clinical practice: If you manage T2D patients, now is the time to ask: Have I considered liver health in this patient? Have I screened for advanced fibrosis? Is my choice of glucose-lowering therapy optimised for both glycaemic and hepatic benefit? Even in settings where hepatology referrals are limited, simple non-invasive tests (e.g., FIB-4) may help stratify risk
By replicating these effects, GLP-1 drugs help regulate metabolism in people with type 2 diabetes and those struggling with obesity
JW and JZ Modifiers: Drug Waste Documentation for Medicare These two modifiers apply to the J-code line, not to CPT 96372
Thus, NAC is an interesting source to fuel the cellular cysteine pool and GSH synthesis modulating the cellular redox homeostasis and the redox capacity of whole organisms